Traditional approaches to obesity management, including lifestyle interventions and older pharmacotherapies, have historically demonstrated limited long-term efficacy, creating an urgent need for more effective therapeutic options
doi: 10.1038/s41467-022-32846-4
Phasic dopamine responses to a food-predictive cue are suppressed by the glucagon-like peptide-1 receptor agonist Exendin-4
However, adjustments may be considered if: Glycaemic targets are not achieved : Your doctor may increase to the next available dose strength Intolerable side effects persist : A temporary dose reduction or slower titration may be appropriate Weight loss plateaus (for weight management indications): Dose optimisation may be discussed Renal function changes : Monitoring may be increased, though most GLP-1s don't require dose adjustment Other medications are added or removed : Particularly other glucose-lowering agents Important considerations during dose changes: Never skip doses or double up if you miss an injectionfollow the specific guidance in your patient information leaflet For missed doses, each product has different instructions: Semaglutide (Ozempic/Wegovy): If within 5 days, take as soon as possible
Colvin, K
These data were confirmed in a pooled analysis of the two trials with a reduction of CRP level with semaglutide of 43% vs 10% with placebo (OR 0.64, 95% C.I
